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INPATIENT MEDICATION UTILIZATION AND
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OBJECTIVES: The objectives of this study were 1) to
compare average total daily study drug cost of risperidone
(n = 120), olanzapine (n = 153), and quetiapine (n = 54)
used as treatment for schizophrenia or schizoaffective 
disorder during an inpatient hospitalization, and 2) to
compare medication utilization.
METHODS: Retrospective data on inpatient drug uti-
lization were collected on 327 patients at three acute
inpatient mental health facilities through 60 days follow-
ing initiation of study drug. All patients with an available
psychiatric history had at least one previous psychiatric
hospitalization. A propensity scoring method, modiﬁed
for three treatment groups, was used to adjust for treat-
ment selection bias. Factors which predicted treatment
selection for all study drugs, for which adjustments were
made, included age, gender, race, and facility.
RESULTS: The average daily study drug cost was $4.35
less for risperidone than olanzapine (95% CI -$5.84, 
-$2.86), and $1.41 less for risperidone than quetiapine
(95% CI -$3.89, $0.81). Between groups, there were 
no statistically signiﬁcant differences in length of stay.
Average daily dose for patients on study drug at time of
discharge was 4.85mg (SD 2.29) for risperidone, 14.22
mg (SD 5.44) for olanzapine, and 368.64mg (SD 230.52)
for quetiapine. Total daily drug cost, including study drug
and concomitant medications, for patients on study drug
at time of discharge was $12.07 (SD 6.53) for risperidone,
$16.33 (SD 6.56) for olanzapine, and $20.22 (SD 42.42)
for quetiapine.
CONCLUSIONS: Using a study design and analysis
aimed at minimizing treatment selection bias, risperidone
patients had a lower daily inpatient study drug cost than
olanzapine (statistically signiﬁcant) and quetiapine (not
statistically signiﬁcant) patients. In addition, differences
in concomitant medication cost and utilization were
present among treatment groups.
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Bipolar disorder is one of the most costly psychiatric 
disorders to treat.
OBJECTIVE: This analysis focuses on (direct) cost out-
comes of a multi-center, randomized, double-blind clini-
cal trial comparing efﬁcacy, safety, effectiveness, and costs
of two ﬁrst-line treatments in acute mania, olanzapine
versus divalproex.
METHODS: The original study included 251 inpatients
with a diagnosis of bipolar I disorder, in an acute manic
or mixed episode. Hospitalization was required for the
ﬁrst week of double-blind treatment, with subsequent 
discharge if clinically appropriate. Inpatient and outpa-
tient resource utilization data were collected at the end 
of the acute phase of the trial (3 weeks), and during 
the maintenance phase (weeks 7, 15, 23, 31, 39, and 47).
Costs were analyzed for all patients who entered the
maintenance phase (olanzapine n = 77, divalproex n =
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70). Acute and maintenance phase costs were estimated
by assigning prices (in year 2000 dollars) from a standard
list to units of applicable medical services. Using a
trimmed-means (25% on each tail of the cost distribu-
tion) comparison to overcome the skewness in the distri-
bution of cost data, the medication treatment groups were
compared.
RESULTS: Overall per-patient costs were not signiﬁcantly
different between the olanzapine-treated patients (15.9 ±
4.5mg/day) and the divalproex-treated patients (1596.4
± 492.7mg/day). However, olanzapine treatment was
associated with signiﬁcantly higher medication costs (p <
.001), but signiﬁcantly lower outpatient (p < .001) and
overall inpatient (p < .05) costs over the course of treat-
ment. Outpatient costs were higher in divalproex-treated
patients due to higher emergency room and other outpa-
tient visits.
CONCLUSIONS: These ﬁndings suggest that differences
in medication acquisition cost are offset by lower costs
for other clinical services during olanzapine treatment.
Further research is needed to determine the extent to
which the present ﬁndings can be generalized to practice
settings outside of the clinical trial context.
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OBJECTIVE: To proﬁle treatment-resistant depression
(TRD) patients healthcare costs and medical care patterns
as their illness progresses.
METHODS: The MEDSTAT MarketScan® Database 
for 1995–2000 was used. Patients with a depression 
diagnosis, suicide attempt, or those treated with electro-
convulsive therapy were considered. TRD patients were
those who either switched or augmented their initial 
four-week (minimum) antidepressant prescription with at
least one more antidepressant prescribed for at least four
weeks. Demographic, treatment, and cost proﬁles were
constructed for periods covered by each subsequent 
antidepressant medication switch or augmentation. Total
medical expenditures per day (year-2000 dollars) were
calculated and compared for periods between the index
date (entry into study) and each subsequent medication
switch or augmentation. Negative binomial count regres-
sion models were used to assess the impact of factors on
number of medication switches or augmentations occur-
ring during the study period.
RESULTS: The sample included 7,737 TRD patients;
72% female, 60% employees and 39% in managed care
plans. The mean number of medication switches or 
augmentations following the index prescription was 2.4.
Average total healthcare expenditures increased 102%
from $563 per month at the initial antidepressant switch
date to $1140 per month after six additional medication
switches or augmentations. The number of medication
switches or augmentations was signiﬁcantly inﬂuenced 
by the following factors: existence of comorbid mental
health problems, type of antidepressant prescribed at the
index date, type of depression diagnosis, treatment under
a managed care plan, single or family insurance coverage,
and length of time patients were followed.
CONCLUSIONS: Most treatment-resistant patients had
multiple medication switches or augmentations. Average
monthly expenditures more than doubled as the TRD
illness progressed through six additional medication
switches or augmentations. A better understanding of
factors associated with the number of medication
switches may lead to promising interventions improving
care for patients with treatment-resistant depression.
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OBJECTIVES: To estimate the long-term health and 
economic impact of treating patients with Alzheimer
disease with galantamine (Reminyl) in different countries.
METHODS: A pharmacoeconomic model, The 
Assessment of Health Economics of Alzheimer’s Disease
(AHEAD), was used to predict the time until Alzheimer’s
disease patients require full-time care and the associated
costs. Full-time care was the consistent requirement for a
signiﬁcant amount of care giving and supervision each
day. Efﬁcacy data were obtained from three clinical trials
comparing galantamine with placebo. For each country,
local data were obtained on service use, balance of care
between community and institutions, and relevant unit
costs. Analyses were completed for The Netherlands,
Sweden, Finland, Germany, UK, Canada and New
Zealand. Forecasts were made for up to ten years. Costs
are reported in 2001 currencies and determined from a
perspective somewhat broader than that of a compre-
hensive payer, including the cost to a national health
service as well as other relevant stakeholders such as
providers of social care services. Both health beneﬁts and
costs were discounted at 3%. Sensitivity analyses were
carried out on key input parameters and combinations of
these parameters.
RESULTS: In each country, full-time care was estimated
to account for at least two-thirds of the cost of caring 
for patients over ten years, and more than 60% of this
cost was from providing institutional care. Galantamine
is predicted to reduce the duration of full-time care by
